Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug
Translational Oncology, 2016 Dasatinib is a common anticancer drug used in the treatment of leukemia. Several side effects have been reported, the most common being myelosuppression, diarrhea, edema, and nausea.
Fidencio Davalos +4 more
doaj +1 more source
Experimental Hematology & Oncology, 2012 Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients.
Gadó Klára +5 more
doaj +1 more source
Optimized Treatment Schedules for Chronic Myeloid Leukemia
, 2016 Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients.
Dingli, David +4 more
core +3 more sources
Glucocorticoid receptor signalling activates YAP in breast cancer [PDF]
, 2017 The Hippo pathway is an oncosuppressor signalling cascade that plays a major role in the control of cell growth, tissue homoeostasis and organ size. Dysregulation of the Hippo pathway leads to aberrant activation of the transcription co-activator YAP ...
Bertolio, Rebecca +12 more
core +3 more sources
The role of lipid metabolism in neuronal senescence
FEBS Open Bio, EarlyView.Disrupted lipid metabolism, through alterations in lipid species or lipid droplet accumulation, can drive neuronal senescence. However, lipid dyshomeostasis can also occur alongside neuronal senescence, further amplifying tissue damage. Delineating how lipid‐induced senescence emerges in neurons and glial cells, and how it contributes to ageing and ...
Dikaia Tsagkari +2 more
wiley +1 more source
Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors. [PDF]
, 2017 ..
Alimena G +7 more
core +1 more source
The Aging Blood: Cellular Origins, Circulating Drivers, and Therapeutic Potential
Aging and Cancer, EarlyView.As a conduit linking all organs, the blood system both reflects and actively drives systemic aging. This review highlights how circulating pro‐aging and antiaging factors and age‐associated hematopoietic stem cell dysfunction contribute to immunosenescence and multi‐organ decline, positioning the hematopoietic system as a target for aging intervention.
Hanqing He, Jianwei Wang
wiley +1 more source
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Journal of Translational Medicine, 2008 Background Metastatic melanoma is a highly chemotherapy resistant tumour. The use of newer targeted therapies alone and in combination with chemotherapy may offer new hope of improving response to treatment. Dasatinib, a multi-target kinase inhibitor, is
Clynes Martin +3 more
doaj +1 more source
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors [PDF]
, 2009 PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists.
Agarwal, Shruti +9 more
core +1 more source
Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones +3 more
wiley +1 more source